Skip to main content
. 2021 Mar 14;13(3):476. doi: 10.3390/v13030476

Figure 2.

Figure 2

Kaplan–Meier analysis of urinary tract cancer-free survival in patients with and without BKVAN. (A) Urinary tract cancer (urothelial carcinoma (UC) and renal cell carcinoma (RCC))-free survival in patients with and without BKPyVAN and non-BKPyVAN was determined by Kaplan–Meier analysis. (B) As the longest observation period was 172 months in patients with BKPyVAN, urinary tract cancer-free survival within 172 months in two groups was assessed by Kaplan–Meier analysis.